Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
REDWOOD CITY, Calif., May 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
